CN Patent

CN120390656A — 环状rna组合物

Assigned to Ona Medical Co · Expires 2025-07-29 · 1y expired

What this patent protects

本文提供了包含IRES和至少一个编码结合分子的表达序列的环状RNA构建体、其组合物和治疗方法，包括用于癌症和自身免疫疾病。特别是，提供了包含IRES和CD19结合子、HER2结合子或BCMA结合子的环状RNA，任选地与递送媒介物一起配制。本文还描述了包含IRES和至少一个编码CAR构建体的表达序列的前体多核苷酸。

USPTO Abstract

本文提供了包含IRES和至少一个编码结合分子的表达序列的环状RNA构建体、其组合物和治疗方法，包括用于癌症和自身免疫疾病。特别是，提供了包含IRES和CD19结合子、HER2结合子或BCMA结合子的环状RNA，任选地与递送媒介物一起配制。本文还描述了包含IRES和至少一个编码CAR构建体的表达序列的前体多核苷酸。

Drugs covered by this patent

Onpattro (PATISIRAN SODIUM) · Alnylam Pharmaceuticals

Patent Metadata

Patent number: CN120390656A
Jurisdiction: CN
Classification: —
Expires: 2025-07-29
Drug substance claim: No
Drug product claim: No
Assignee: Ona Medical Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.